Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | +1.21% | -4.02% | +4.38% |
03-28 | Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 55.81M 4.47B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.8B | Net income 2025 * | -22M -1.76B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.69
x | P/E ratio 2025 * |
-3.21
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97% |
1 day | +1.21% | ||
1 week | -4.02% | ||
Current month | +0.60% | ||
1 month | +1.21% | ||
3 months | +1.21% | ||
6 months | -79.12% | ||
Current year | +4.38% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 08/12/20 |
Michael Grey
FOU | Founder | 71 | 21/09/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 21/09/14 |
Director/Board Member | 64 | 30/11/17 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 19/01/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.67 | +1.21% | 115,223 |
25/04/24 | 1.65 | -1.79% | 119,607 |
24/04/24 | 1.68 | +0.30% | 138,374 |
23/04/24 | 1.675 | -0.89% | 78,144 |
22/04/24 | 1.69 | -2.87% | 181,894 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.38% | 55.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RPHM Stock